1 Two phase III studies—Avastin for Renal Cell Cancer (AVOREN) 7 and Cancer and Leukemia Group B (CALGB) 90206 8 indicated significant improvements in PFS for bevacizumab plus interferon-α ...

Chung et al. examine the levels of glycoprotein non-metastatic melanoma protein B (GPNMB) in the blood of patients with renal cell carcinoma who acquire resistance to immune checkpoint inhibitor ...